Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Cardeas Pharma Corp.
Seattle, Washington, United Statescardeaspharma.com ↗
- Ownership
- Private
- Employees
- ~10
- Development stage
- Other
01
Overview
Cardeas Pharma developed inhaled antibiotic therapies for serious hospital-acquired respiratory infections using a proprietary nebulizer system. Clinical studies included completed Phase 1 and Phase 2 trials evaluating the safety and efficacy of aerosolized amikacin/fosfomycin combinations delivered via the eFlow system to both healthy volunteers and mechanically ventilated patients. Some later-stage clinical programs were withdrawn or not advanced further as of last updates.[1][3][6]
- Therapeutic areas
- Infectious Diseases
- Modalities
- Inhaled antibiotics (combination of small molecules)
- Industry
- Biotech
Beyond the preview
Go deeper on Cardeas Pharma Corp..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cardeas Pharma Corp..